Singapore markets close in 4 minutes

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.10-0.02 (-0.18%)
At close: 04:00PM EDT
11.08 -0.02 (-0.18%)
After hours: 07:48PM EDT

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees38,000

Key executives

NameTitlePayExercisedYear born
Mr. Scott Andrew SmithCEO & DirectorN/AN/A1962
Mr. Anthony MauroPresident of Developed Markets9.39MN/A1973
Ms. Theodora MistrasChief Financial OfficerN/AN/AN/A
Mr. Sanjeev Kumar SethiChief Operating OfficerN/AN/A1967
Mr. Paul B. CampbellChief Accounting Officer, Senior VP & Corporate ControllerN/AN/A1968
Mr. Ramkumar V. RayapureddyChief Information OfficerN/AN/AN/A
Mr. Brian S. RomanGlobal General CounselN/AN/A1970
Mr. David BaylesChief Compliance OfficerN/AN/AN/A
Ms. Jennifer MauerHead of Global Communications & Corporate BrandN/AN/AN/A
Mr. Andrew EnriettiChief Human Relations OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Corporate governance

Viatris Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.